Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Menlo Therapeutics Inc (MNLO)

Menlo Therapeutics Inc (MNLO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Menlo Therapeutics Reports Second Quarter 2019 Financial Results and Provides Program Updates Including Accelerated Timeline for Upcoming Clinical Data

Results from Serlopitant Phase 2 Clinical Trial for the Treatment of Chronic Pruritus of Unknown Origin Anticipated in Q1 2020

MNLO : 3.42 (+4.59%)
Menlo Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference

Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta, Menlo's...

MNLO : 3.42 (+4.59%)
Life Science Company Live Investor Presentations Now Available for On-Demand Viewing

Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the July 11th life sciences conference are now available for on-demand viewing...

MNLO : 3.42 (+4.59%)
NGW.CN : 0.245 (unch)
LXX.CN : 1.130 (+2.73%)
Life Science Company Live Investor Conference July 11th

Life science company executives will share vision and answer audience questions at VirtualInvestorConferences.com

MNLO : 3.42 (+4.59%)
NGW.CN : 0.245 (unch)
LXX.CN : 1.130 (+2.73%)
Menlo Therapeutics to Present at Upcoming Investor Conferences

Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta, Chief Executive...

MNLO : 3.42 (+4.59%)
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Menlo Therapeutics, Inc. of Class Action Lawsuit

The following statement is being issued by Levi & Korsinsky, LLP:

MNLO : 3.42 (+4.59%)
Menlo Therapeutics Reports First Quarter 2019 Financial Results

Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced financial results for the...

MNLO : 3.42 (+4.59%)
Menlo Therapeutics to Present at the Class of 2018 Biotech IPOs Investor Day

Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta, Chief Executive...

MNLO : 3.42 (+4.59%)
New Research: Key Drivers of Growth for Geron, Hess, Royal Gold, Lear, Menlo Therapeutics, and CorEnergy Infrastructure Trust -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Geron Corporation (NASDAQ:GERN),...

MNLO : 3.42 (+4.59%)
CORR : 45.16 (-0.02%)
HES : 59.82 (+0.34%)
LEA : 108.97 (+2.79%)
GERN : 1.41 (+1.44%)
RGLD : 124.64 (-0.31%)
Menlo Therapeutics Announces Publication of Serlopitant Phase 2 Data for the Treatment of Pruritus Associated with Prurigo Nodularis

Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced the publication of the company's...

MNLO : 3.42 (+4.59%)
Menlo Therapeutics Announces New Board Member Elisabeth Sandoval

Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Elisabeth Sandoval has...

MNLO : 3.42 (+4.59%)
ALDR : 9.59 (+3.68%)
Menlo Therapeutics to Present at the 31st Annual ROTH Conference

Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that management will present...

MNLO : 3.42 (+4.59%)
Menlo Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced financial results for the...

MNLO : 3.42 (+4.59%)
Menlo Therapeutics Announces Late-Breaking Oral Presentation at the American Academy of Dermatology Annual Meeting

Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that an abstract has been...

MNLO : 3.42 (+4.59%)
Report: Developing Opportunities within Incyte, Burlington Stores, Hannon Armstrong Sustainable Infrastructure Capital, iRobot, Lear, and Menlo Therapeutics -- Future Expectations, Projections Moving into 2019

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Incyte Corporation (NASDAQ:INCY),...

MNLO : 3.42 (+4.59%)
BURL : 172.13 (+2.08%)
INCY : 83.12 (+3.11%)
IRBT : 65.22 (+2.31%)
LEA : 108.97 (+2.79%)
HASI : 27.17 (+1.27%)
Lawsuit for Investors in NASDAQ: MNLO shares against Menlo Therapeutics Inc. announced by Shareholders Foundation

The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in NASDAQ: MNLO shares over alleged securities laws violations by Menlo Therapeutics Inc. in connection with the...

MNLO : 3.42 (+4.59%)

Van Meerten Stock Picks

AMD - Volume Leader
The Volume Leader today is the semiconductor company Advanced Micro Devices (AMD).
AMD +1.51
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar